Ranbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety c...

Reacting to the news, shares of the drug maker plunged as much as 2.3 per cent in trade on the BSE, but recouped early morning losses quick...

The USFDA prohibited Ranbaxy Labs from manufacturing and distributing APIs from its Toansa plant for FDA-regulated drug products.

Rejecting sabotage theory at Toansa plant that faces USFDA ban, Ranbaxy denied blaming company's voluntary retirement scheme for problems i...

Analysts have maintained their cautious stance on Ranbaxy Laboratories even though the drugmaker reported a drastic drop in net loss.

Days after US FDA banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU & UK have said they are evalu...

Two senior US officials -- Chief of FDA and Head of US EXIM Bank -- will be in India, hoping to give momentum to bilateral dialogues.

Toansa is the key active pharmaceutical ingredients facility and an alert is likely to put further pressure on business at least in the sho...

The USFDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.

Ranbaxy Laboratories Ltd plunged as much as 19.90 per cent in trade on Friday, after the US Food and Drug Administration import alert.

The FDA said the drugmaker is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.

Terming the USFDA ban on its Toansa plant 'disappointing', Ranbaxy Laboaratories today said it will take 'appropriate management action' fo...

Ranbaxy Labs plunged as much as 19.69% , after the USFDA ban effectively stops the company from shipping drugs from its Toansa plant.

Macquarie and Jefferies downgraded Ranbaxy, saying the FDA uncertainty could put pressure on valuations in the near-term till further clari...

The US Food and Drug Administration's observations regarding the manufacturing practices in the company's plant in Punjab.

The Toansa plant is crucial for the company as about 70 per cent of APIs used in its formulations are said to be manufactured there.

Shares of Ranbaxy Laboratories are near day's low as sentiment turned bearish on reports that two of its plants are under USFDA scanner.